<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">Broad-spectrum antibiotic use puts patients at risk for developing 
 <italic>Clostridium difficile</italic> colitis (CDI). A recent Cochrane review emphasized increased symptomatic cure with vancomycin when compared to metronidazole, fidaxomicin compared to vancomycin, and possibly teicoplanin compared to vancomycin [
 <xref ref-type="bibr" rid="CR24">24</xref>] in CDI patients. Importantly, no recent studies looked at optimal treatment of severe 
 <italic>C. difficile</italic> colitis [
 <xref ref-type="bibr" rid="CR24">24</xref>].
</p>
